[
    [
        {
            "time": "",
            "original_text": "睿昂基因拟募资超总资产 产品价降 上半年应收账款超营收 盈利能力下降",
            "features": {
                "keywords": [
                    "睿昂基因",
                    "募资",
                    "总资产",
                    "产品降价",
                    "应收账款",
                    "营收",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "睿昂基因拟募资超总资产 产品价降 上半年应收账款超营收 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        }
    ]
]